AstraZeneca Pharmaceuticals LP
1 MedImmune Way
2756 articles about AstraZeneca Pharmaceuticals LP
Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively.
The Oncologic Drugs Advisory Committee voted 11–1 supporting Merck’s and AstraZeneca’s PARP inhibitor for metastatic castration-resistant prostate cancer patients with BRCA mutations.
Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer.
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus in the United States.
Sobi to streamline nirsevimab contractual arrangements
Sobi® announced a streamlining and simplification of the contractual economics for nirsevimab.
AstraZeneca’s Imfinzi and Lynparza met primary endpoint markers in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to data released Wednesday.
Compass Group and AstraZeneca Expand Activities Focused on Innovation and Shared Success
Continuing a shared commitment to innovation, Compass Group, the world’s largest food and facility services company, and AstraZeneca, the global, science-led, patient-focused pharmaceutical company, are taking supplier management to the next level.
Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca
Salipro Biotech announces the publication of results from a collaboration with AstraZeneca.
AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Personalis, Inc. (Nasdaq: PSNL) today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.
ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZeneca’s ENHERTU® met the pre-specified target for objective response rate and demonstrated durable response across multiple HER2 expressing advanced solid tumors in heavily pre-treated patients.
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology Annual Meeting, April 22-27, 2023.
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental new drug application (sNDA) for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.
ASTRAZENECA ANNOUNCES MAJOR INVESTMENT IN ONTARIO'S LIFE SCIENCES SECTOR
AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada.
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
Keymed Biosciences Inc., and Lepu Biopharma Co., Ltd, jointly announce a global exclusive licence agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate.
The FDA accepted the BLA for and granted Pfizer's maternal RSV vaccine candidate priority review.